ASCO Annual Meeting: Lung Cancer

Videos

CancerNetwork® sat down with Jonathan Spicer, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about how communication across a multidisciplinary team was necessary to the success of neoadjuvant immunotherapy administration in CheckMate 816.

Jonathan Spicer, MD, PhD, Discusses Multidisciplinary Communication for Treating Resectable NSCLC With Neoadjuvant Immunotherapy 

At ASCO 2021, CancerNetwork® spoke with Stephen Liu, MD, about his research on the ARROW trial and how these results might impact the treatment of patients with RET fusion–positive non–small cell lung cancer who are potential candidates for treatment with pralsetinib. 

Stephen Liu, MD, on Key Takeaways From the ARROW Trial of Pralsetinib for RET+ NSCLC

CancerNetwork® sat down with John Heymach, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk adjuvant immunotherapy for recurrence-free survival in resected non–small cell lung cancer. 

John Heymach, MD, PhD, Discusses the Use of Adjuvant Immunotherapy for Patients With NSCLC 

At the 2021 ASCO Annual Meeting, Stephen Liu, MD, discussed the important of findings from the ARROW trial of pralsetinib in patients with RET-altered non–small cell lung cancer. 

Stephen Liu, MD, on How Targeted Therapy Results in Significant Efficacy for RET-Altered Tumors

Jabbour detailed the importance of managing care in a multidisciplinary setting for patients enrolled in the KEYNOTE-799 trial with stage III NSCLC.

Salma K. Jabbour, MD, Discusses the Value of Treating Patients With NSCLC in a Multidisciplinary Setting

Articles

According to data presented at the 2021 ASCO Annual Meeting, patients with crizotinib-refractory ALK-positive non–small cell lung cancer demonstrated long-term response and survival maintenance on brigatinib.


Long-Term Efficacy Continues With Brigatinib in ALK+ NSCLC After Crizotinib

Larotrectinib’s tumor-agnostic indication for NTRK fusion–positive cancers is further validated by data presented at the 2021 ASCO Annual Meeting.

Long-Term Efficacy Data Continues to Support Larotrectinib Use for Tumor With NTRK Fusions

The addition of neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathological complete response rates and showed a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Adding Nivolumab to Chemotherapy Improves Outcomes in Resectable NSCLC 

Although adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer, the agent did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

Adjuvant Gefitnib Fails to Induce Superior DFS, OS Versus Chemo in EGFR-mutant NSCLC

Patients with platinum-pretreated EGFR exon 20 insertion mutation–positive metastatic non–small cell lung cancer experienced antitumor activity with oral TKI mobocertinib, according to results presented at the 2021 ASCO Annual Meeting.

ASCO Annual Meeting: Lung Cancer | Conference